TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zydus Lifesciences Limited ( (IN:ZYDUSLIFE) ) has shared an update.
Zydus Lifesciences Ltd., through its subsidiary Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV for the generic version of Ozanimod Capsules, targeting the U.S. market. This collaboration allows Zydus to commercialize the product in the U.S., while Synthon will handle regulatory approval and manufacturing. The agreement positions Zydus to enhance its presence in the U.S. pharmaceutical market, particularly in the treatment of multiple sclerosis and ulcerative colitis, and reflects its strategic focus on expanding access to essential medicines.
More about Zydus Lifesciences Limited
Zydus Lifesciences Ltd. is a global innovation-driven healthcare company that focuses on advancing care in therapeutic areas and making essential medicines more accessible to patients. The company operates in the pharmaceutical industry, providing a range of healthcare products and services.
Average Trading Volume: 52,391
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1002.4B INR
See more data about ZYDUSLIFE stock on TipRanks’ Stock Analysis page.